Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial - Wikidata - thesis-toulmin - TriplyDB

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

http://www.wikidata.org/entity/Q29615711

about

Targeted therapy for advanced renal cell carcinoma mTOR inhibitors in advanced renal cell carcinoma Axitinib for the management of metastatic renal cell carcinoma State of the science: an update on renal cell carcinoma New advances in targeted gastric cancer treatment Contemporary Treatment of Metastatic Renal Cell Carcinoma A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma Pazopanib in the management of advanced soft tissue sarcomas Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Pazopanib in the treatment of advanced renal cell carcinoma Chinese guidelines on the management of renal cell carcinoma (2015 edition)Oral targeted therapy for cancer Sequence of treatment in locally advanced and metastatic renal cell carcinoma Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors Cytoreductive surgery in the era of targeted molecular therapy Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review Molecular Targeted Therapies of Aggressive Thyroid Cancer Profile of nintedanib in the treatment of solid tumors: the evidence to date Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicine More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses Therapeutic challenges in renal cell carcinoma Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials Pazopanib in sarcomas: expanding the PALETTE Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer Role of immunotherapy for renal cell cancer in 2011 Differentiating mTOR inhibitors in renal cell carcinoma Targeting angiogenesis in squamous non-small cell lung cancer Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence Targeted therapies and the treatment of non-clear cell renal cell carcinoma

P2860

Q24242946-C04E86A6-DC03-45F3-9E26-39DEF7FC3F9A Q24612127-E3E0D1AD-0531-43B5-B8D4-ABB6F1713E90 Q24613720-A5CAE8C9-D10F-474A-8702-37F16BC87601 Q24630685-880E0076-A92C-4B3A-A29B-3C35B236163C Q26738548-134C548A-75DD-4968-A1CB-9D82D92C217D Q26740594-790D2450-54FC-4EE2-8826-4FC9028D1B99 Q26741817-85062E2E-132F-4102-965C-4DAE2DEE42B4 Q26746205-95D33E9A-D2FB-4BDA-A00B-3B51365F5348 Q26747767-12761788-D3EE-404F-AA1F-DFA240E54D60 Q26751341-5D5956C1-044F-4587-9DC1-F7C34C14A64A Q26752381-5EFDA1F6-E631-48BD-ACE7-1F3974ADA245 Q26764892-6E6C0F8C-DF4D-4152-9D71-30BB20AB5938 Q26766240-D2CA3299-B42C-416B-AE5F-AE45BB9CEB09 Q26770413-9DEC264B-0A6A-42A3-941A-E16BD8D6E9CA Q26772206-389FA1F8-4F5E-4A83-908D-0A5DFB1BA3CC Q26773240-ECDD414E-A1EE-443B-90C3-650B47FBE011 Q26773653-9FB0E9FA-4567-40EB-B04C-5C7F912EE201 Q26773795-DB6FAA9A-1161-43A7-B6F3-1ED20A7DE567 Q26774134-D652D982-0582-44B4-B375-6F52B8C25A03 Q26774515-82B73E65-87CB-4B9C-9BB7-9E979324BBD9 Q26774734-EC6E90A0-21F4-4E55-826D-678AA42A8F03 Q26775134-806C1D67-C67F-46F2-B711-C6741852466E Q26779144-5EB3D732-B45C-48C9-B33C-8923880A4F9A Q26781662-D5B464C3-8EC8-4AFA-9A32-59E0FAAA5E8F Q26783514-B3B1C1AF-C564-4164-9EEC-E841070D76B2 Q26783520-9E7C1E03-D0F7-40DA-B9D1-B56332C3E42D Q26786243-4BE85543-9DCE-4C6D-8544-A2DC67DF29A8 Q26796702-D0740A37-3FBB-460E-BDD3-0F9BA75249E9 Q26801279-4551C0CE-6122-47AC-B590-3AFEDFDB6214 Q26822790-E823738B-25EA-4A14-8886-C69B198E4F90 Q26825050-AABE7CC5-1589-4BA3-ABCF-1D9E60C2C020 Q26827319-90D2DF77-62DE-4A01-857F-29B78C180D98 Q26852437-DEFAC381-A5C4-47EB-B75D-C535F43FA894 Q26852704-F98CBC62-0330-4457-985F-8EB4A0ABBB1B Q26853453-0D0D255C-35A5-4EF6-938D-272285CBAB51 Q26860172-6A046D7E-E35D-4E79-969C-30069F6D3BD8 Q26861341-EE4B63A8-92B0-4D61-AE0E-1F545B982157 Q26865766-08DDC764-3B13-45FB-925E-9A65A9711D1F Q26865789-847B456E-AC99-4844-977A-2FAFDA247450 Q26995391-A2E8AE4D-ECF8-4779-887E-D0201FAD218D

P2860

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

http://www.wikidata.org/entity/Q29615711

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Pazopanib in locally advanced ...... f a randomized phase III trial

@ast

Pazopanib in locally advanced ...... f a randomized phase III trial

@en

type

label

Pazopanib in locally advanced ...... f a randomized phase III trial

@ast

Pazopanib in locally advanced ...... f a randomized phase III trial

@en

prefLabel

Pazopanib in locally advanced ...... f a randomized phase III trial

@ast

Pazopanib in locally advanced ...... f a randomized phase III trial

@en

P1433

Q29615711-DAF3FED9-1A55-4248-AB29-DA038543D3DD

P1476

Q29615711-C6DC1AAA-2E74-4397-BF5C-F3E0703C8355

P2093

Q29615711-055ABC41-5E82-43E8-BC6E-99FFA5C98C09

Q29615711-0B19C8A4-65AC-470A-AF65-D07553602169

Q29615711-20AC14A5-4C41-44E7-AC75-187E0CFCAB13

Q29615711-221D3E56-4FED-4149-BBEB-C7E870AC08D7

Q29615711-22EE7777-819D-464F-ABCC-27FF0A9E9A4C

Q29615711-456E097C-9C1C-4865-9103-9485A70FE4D3

Q29615711-4F11C9AA-B46E-45C1-AB72-B03BE9F0C75A

Q29615711-503C49AC-2D78-44DA-B368-56C1C25CBCED

Q29615711-6B3DE202-AFCC-41DF-9B31-BEE01B1C2AD8

Q29615711-A6C9437C-07EC-43C0-A399-12933D7CCC0E

P304

Q29615711-71522ED4-59D1-43DF-AC7A-98D27394BEF2

P31

Q29615711-1FA25574-331E-4079-ADA5-3869188A8A99

P3181

Q29615711-481B366A-5CAF-4105-AD75-5CC6916414F7

P356

Q29615711-118B6561-E086-4503-BB29-112AB880AE40

P407

Q29615711-7C2B0A31-5964-44FC-B500-0C1169D3FAAB

P433

Q29615711-C628A162-BD9B-4598-928C-073C2039BC01

P478

Q29615711-3381BFE7-6731-4FF4-8D71-8B4A07C4720B

P50

Q29615711-7CEB84BF-6D63-4A8E-8189-A14643AB27D7

P577

Q29615711-B240B92A-5584-4555-A412-515145EF9057

P698

Q29615711-E218DD35-8989-46B1-8044-22806857D408

P921

Q29615711-BF767F72-5B60-4070-87D6-F1F59DAF83DD

P3181

P356

JCO.2009.23.9764

P1433

Journal of Clinical Oncology

P1476

Pazopanib in locally advanced ...... f a randomized phase III trial

@en

P2093

Barrios CH

http://www.w3.org/2001/XMLSchema#string

Chen M

http://www.w3.org/2001/XMLSchema#string

Davis ID

http://www.w3.org/2001/XMLSchema#string

Gladkov OA

http://www.w3.org/2001/XMLSchema#string

Hawkins RE

http://www.w3.org/2001/XMLSchema#string

Kavina A

http://www.w3.org/2001/XMLSchema#string

Lee E

http://www.w3.org/2001/XMLSchema#string

Mardiak J

http://www.w3.org/2001/XMLSchema#string

McCann L

http://www.w3.org/2001/XMLSchema#string

Pandite L

http://www.w3.org/2001/XMLSchema#string

P304

1061-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

19142

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2009.23.9764

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Cezary Szczylik

P577

2010-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20100962

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial